Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?
Read More Pharma Industry News Bristol Myers Squibb’s subcutaneous nivolumab shows promise in Phase 3 RCC trial Bristol Myers Squibb (NYSE: BMY) has announced results from its Phase 3 CheckMate -67T trial, which could revolutionize… byPallavi MadhirajuJanuary 29, 2024